c-Met is a marker of pancreatic cancer stem cells and therapeutic target.

BACKGROUND & AIMS Growth of many different tumor types requires a population of self-renewing cancer stem cells (CSCs). c-Met is a marker of normal mouse pancreatic stem and progenitor cells; we investigated whether it is also a marker of human pancreatic CSCs that might be developed as a therapeutic target. METHODS We studied growth of primary human pancreatic adenocarcinoma in NOD SCID mice. The self-renewal capability of pancreatic cancer cells that expressed high levels of c-Met (c-Met(high)) was assessed using in vitro sphere assays and compared with those that were c-Met negative or expressed low levels of c-Met. The tumorigenicity of c-Met(high) pancreatic cancer cells was evaluated in NOD SCID mice. RESULTS c-Met(high) cells readily formed spheres, whereas c-Met-negative cells did not. Use of the c-Met inhibitor XL184 or c-Met knockdown with small hairpin RNAs significantly inhibited tumor sphere formation. c-Met(high) cells had increased tumorigenic potential in mice; those that expressed c-Met and CD44 (0.5%-5% of the pancreatic cancer cells) had the capability for self-renewal and the highest tumorigenic potential of all cell populations studied. In pancreatic tumors established in NOD SCID mice, c-Met inhibitors slowed tumor growth and reduced the population of CSCs when given alone or in combination with gemcitabine. Administration of XL184 for 2 weeks after cardiac injection of cancer cells prevented the development of metastases. CONCLUSIONS c-Met is a new marker for pancreatic CSCs. It is required for growth and metastasis of pancreatic tumors in mice and is a therapeutic target for pancreatic cancer.

[1]  D. Schiff,et al.  XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. , 2010, IDrugs : the investigational drugs journal.

[2]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[3]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[4]  M. Roger,et al.  Endogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular Zone Neural Stem Cell Amplification and Self‐Renewal , 2009, Stem cells.

[5]  Jiaquan Xu,et al.  Deaths: final data for 2005. , 2008, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[6]  D. Simeone,et al.  Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. , 2008, Translational oncology.

[7]  D. Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[8]  G. Gallick,et al.  Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.

[9]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[10]  M. Ratain,et al.  A phase I dose-escalation study of the safety and pharmacokinetics (PK) of XL184, a VEGFR and MET kinase inhibitor, administered orally to patients (pts) with advanced malignancies , 2007 .

[11]  L. Ellis,et al.  Tyrosine kinase receptor RON in human pancreatic cancer , 2007, Cancer.

[12]  N. Ohkohchi,et al.  Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. , 2007, Gastroenterology.

[13]  Linheng Li,et al.  Normal stem cells and cancer stem cells: the niche matters. , 2006, Cancer research.

[14]  B. Petersen,et al.  AUTOIMMUNE PANCREATITIS: DIAGNOSIS USING HISTOLOGY, IMAGING, SEROLOGY, OTHER ORGAN INVOLVEMENT AND RESPONSE TO STEROIDS , 2005 .

[15]  P. Comoglio,et al.  Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.

[16]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[17]  H. Nakauchi,et al.  Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. , 2004, Diabetes.

[18]  M. Uhler,et al.  A Transforming Growth Factor β-Induced Smad3/Smad4 Complex Directly Activates Protein Kinase A , 2004, Molecular and Cellular Biology.

[19]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[20]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[21]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Ohuchida,et al.  Co-cultivation of pancreatic cancer cells with orthotopic tumor-derived fibroblasts: fibroblasts stimulate tumor cell invasion via HGF secretion whereas cancer cells exert a minor regulative effect on fibroblasts HGF production. , 2003, Cancer letters.

[23]  J. Sleeman,et al.  CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.

[24]  K. Herzig,et al.  c‐met Expression in Pancreatic Cancer and Effects of Hepatocyte Growth Factor on Pancreatic Cancer Cell Growth , 1997, Pancreas.

[25]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[26]  M. Tsao,et al.  Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. , 1995, The American journal of pathology.

[27]  Carmen Birchmeier,et al.  Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud , 1995, Nature.

[28]  R. Poulsom,et al.  Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. , 1995, Cancer research.

[29]  H. Friess,et al.  Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. , 1994, Cancer research.

[30]  C. Birchmeier,et al.  Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development , 1993, The Journal of cell biology.

[31]  E Medico,et al.  Expression of the Met/HGF receptor in normal and neoplastic human tissues. , 1991, Oncogene.

[32]  C. Cooper,et al.  Molecular cloning of a new transforming gene from a chemically transformed human cell line , 1984, Nature.

[33]  F. Schmitz,et al.  C-met protooncogene expression and its regulation by cytokines in the regenerating pancreas and in pancreatic cancer cells. , 2000, Scandinavian journal of gastroenterology.

[34]  P. Comoglio,et al.  Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. , 1993, EXS.

[35]  B. Davidson,et al.  The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001. , 2022 .